Simeone X , Siebert DCB , Bampali K , Varagic Z , Treven M , Rehman S , Pyszkowski J , Holzinger R , Steudle F , Scholze P , Mihovilovic MD , Schnürch M , Ernst M .

W 1232 Austrian Science Fund FWF

	Figure 1. Chemical structures of the ligands (1–7) employed in this study. The letters “A, B, C and D” refer to the different rings in the scaffold. The position and numbering of the residues (R6, R8 and R′4) are depicted in the general structure (bottom right corner). The nomenclature “chloro-methoxy” or “methoxy-methoxy” respectively describes first the residue in position R8 and then the residue in position R′4. For compound 7 residues in position R8-R6-R′4 are indicated.
	Figure 2. Compound 1 modulates GABA-evoked currents from α1β3, α1β3γ2 and α1β3δ similarly. Concentration-dependent modulation of GABA EC3–5 current at α1β3, α1β3γ2 and α1β3δ. Data represent means ± SEM (n = 3–8). α1β3 and α1β3γ2 data are identical with those published previously22.
	Figure 3. Compounds 1–6 show potency selectivity for β1-containing receptors. Dose-response data of compounds 1–6 at α1β1, α1β2 and α1β3 subunit combinations; (a–c) Left, aggregate dose-response curves of R8 = chloro compounds 1–3 co-applied with GABA EC3–5. Right, EC50 values obtained by fitting data of each cell individually; (d–f) Left, aggregate dose-response curves of R8 = methoxy compounds 4–6 co-applied with GABA EC3–5. Right, EC50 values obtained by fitting data of each cell individually. Highest potency was consistently observed at α1β1 receptors. Compound 6 (f) lacked efficacy at α1β2 and α1β3, therefore EC50 values could not be obtained. In those instances where high compound concentrations elicited substantial desensitization (see panels a, c, d, f and sample traces in (g,h)), the highest compound concentration was excluded from the fit. Statistically significant differences were assessed by one-way ANOVA with Tukey’s multiple comparison test; *p < 0.05, ***p < 0.01, ****p < 0.001, *****p < 0.0001, n.s. = not significant, n.d. = not determined. n = 3–8. (g–i) Sample traces obtained with compound 1. Note the desensitization in α1β1 (g) at 10 µM and 30 µM, increasingly limiting maximum current amplitudes. Tabulated data corresponding to panels a–f are provided in Supplementary Tables S1–S6. Additional sample traces are provided in Supplementary Fig. S7.
	Figure 4. Comparison of EC50 and maximum efficacy among α1β1, α1β3 and α1β3N41R. (a,b) The plots show the mean EC50 on the x-axis (note that the axis is broken to accommodate the range) and the mean maximum efficacy at 10 μM (% of control current at EC3–5) on the y-axis (note the different scales on the two panels) of compounds 1–6. The difference between wild type α1β3 and α1β3N41R is indicated with a black arrow, statistically significant EC50 differences are indicated. The potency differences between α1β3 and α1β3N41R for compounds 1, 3 and 4 are statistically significant (**,**,****, respectively). Arrows pointing to the left show a decrease of the EC50 value between wild type and mutated receptors, which corresponds to an increase in potency. Simultaneously, changes in efficacy can be seen (arrows with upward or downward component indicating increase or decrease in maximum efficacy, respectively). The values obtained with wild type α1β3 and α1β1 receptors are connected with a blue dotted line. The dotted purple line visualizes the difference between α1β1 and α1β3N41R. The EC50 values for the mutated receptors are 0.98 µM, 3.44 µM, 0.2 µM, 1.2 µM, 2.47 µM and 1.87 µM for compounds 1–6, respectively. EC50 values were calculated for each individual experiment and are presented as mean ± SEM. Statistically significant differences were assessed by one-way ANOVA with Tukey’s multiple comparison test. Note that the EC50 value of compound 6 in α1β3 receptors is not depicted, since this compound has nearly no efficacy in this receptor subtype. Bars indicate mean ± SEM, n = 3–8. The dose-response curves of compounds 1–6 in α1β3N41R receptors are depicted in Supplementary Fig. S12.
	Figure 5. Compound 1 modulates GABA-evoked currents in α1β1, α1β1γ1 and α1β1δ receptors with similar potencies. (a) Concentration-dependent modulation of GABA EC3–5 current at α1β1, α1β1γ1 and α1β1δ. Data represent means ± SEM (n = 3–10). (b) EC50 values were calculated for each individual experiment and are presented as mean ± SEM. One-Way ANOVA was used for multiple comparisons followed by a Tukey post hoc test and showed no significant differences between the mean EC50 values for each subtype.
	Figure 6. Compound 7 modulates GABA-evoked currents in α1β1, α1β1γ1 and α1β1δ receptors. (a,b) Concentration-dependent modulation of GABA EC3–5 current at α1β1, α1β1γ1 and α1β1δ receptors. Data represent means ± SEM (n = 4–17) (see Supplementary Table S19).

Akinci, Widespread expression of GABA(A) receptor subunits in peripheral tissues. 1999, Pubmed

Akinci, Widespread expression of GABA(A) receptor subunits in peripheral tissues. 1999, Pubmed
Andersson, PET radioligands targeting the brain GABAA /benzodiazepine receptor complex. 2013, Pubmed
Anstee, Mutations in the Gabrb1 gene promote alcohol consumption through increased tonic inhibition. 2013, Pubmed
Che Has, Zolpidem is a potent stoichiometry-selective modulator of α1β3 GABAA receptors: evidence of a novel benzodiazepine site in the α1-α1 interface. 2016, Pubmed , Xenbase
Cheng, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. 1973, Pubmed
Curtis, Glycine, strychnine, picrotoxin and spinal inhibition. 1969, Pubmed
Dillon, U-93631 causes rapid decay of gamma-aminobutyric acid-induced chloride currents in recombinant rat gamma-aminobutyric acid type A receptors. 1993, Pubmed
Ebert, Extensive heterogeneity of recombinant gamma-aminobutyric acidA receptors expressed in alpha 4 beta 3 gamma 2-transfected human embryonic kidney 293 cells. 1996, Pubmed
Fryer, Structure-activity relationship studies at the benzodiazepine receptor (BZR): a comparison of the substitutent effects of pyrazoloquinolinone analogs. 1993, Pubmed
Gröll, Selective Ru(0)-catalyzed deuteration of electron-rich and electron-poor nitrogen-containing heterocycles. 2012, Pubmed
He, Studies of molecular pharmacophore/receptor models for GABAA/BzR subtypes: binding affinities of symmetrically substituted pyrazolo[4,3-c]quinolin-3-ones at recombinant alpha x beta 3 gamma 2 subtypes and quantitative structure-activity relationship studies via a comparative molecular field analysis. 1999, Pubmed
Hibbs, Principles of activation and permeation in an anion-selective Cys-loop receptor. 2011, Pubmed
Hill-Venning, Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor. 1997, Pubmed , Xenbase
Hirschberg, Oral absorption of CGS-20625, an insoluble drug, in dogs and man. 1995, Pubmed
Johnston, Advantages of an antagonist: bicuculline and other GABA antagonists. 2013, Pubmed
Jurd, General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit. 2003, Pubmed
Kelley, Alterations in Purkinje cell GABAA receptor pharmacology following oxygen and glucose deprivation and cerebral ischemia reveal novel contribution of β1 -subunit-containing receptors. 2013, Pubmed
Khom, Pharmacological properties of GABAA receptors containing gamma1 subunits. 2006, Pubmed , Xenbase
Khom, Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. 2007, Pubmed , Xenbase
Korpi, Cerebellar GABAA receptors in two rat lines selected for high and low sensitivity to moderate alcohol doses: pharmacological and genetic studies. 1992, Pubmed
Kucken, Structural requirements for imidazobenzodiazepine binding to GABA(A) receptors. 2003, Pubmed
Lingford-Hughes, Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. 2002, Pubmed
Maeda, Visualization of alpha5 subunit of GABAA/benzodiazepine receptor by 11C Ro15-4513 using positron emission tomography. 2003, Pubmed
Maldifassi, Molecular mode of action of CGS 9895 at α1 β2 γ2 GABAA receptors. 2016, Pubmed , Xenbase
Miller, Crystal structure of a human GABAA receptor. 2014, Pubmed
Mirheydari, Unexpected Properties of δ-Containing GABAA Receptors in Response to Ligands Interacting with the α+ β- Site. 2014, Pubmed , Xenbase
Mortensen, GABA Potency at GABA(A) Receptors Found in Synaptic and Extrasynaptic Zones. 2011, Pubmed
Neumann, Palladium-catalyzed amidation of unactivated C(sp(3))-H bonds: from anilines to indolines. 2009, Pubmed
Olsen, International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. 2008, Pubmed
Pan, Cu-Catalyzed Intramolecular Amidation of Unactivated C(sp(3) )-H Bonds To Synthesize N-Substituted Indolines. 2016, Pubmed
Puthenkalam, Structural Studies of GABAA Receptor Binding Sites: Which Experimental Structure Tells us What? 2016, Pubmed
Ramerstorfer, The point mutation gamma 2F77I changes the potency and efficacy of benzodiazepine site ligands in different GABAA receptor subtypes. 2010, Pubmed
Ramerstorfer, The GABAA receptor alpha+beta- interface: a novel target for subtype selective drugs. 2011, Pubmed , Xenbase
Sanna, Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. 1996, Pubmed , Xenbase
Savini, High affinity central benzodiazepine receptor ligands. Part 2: quantitative structure-activity relationships and comparative molecular field analysis of pyrazolo[4,3-c]quinolin-3-ones. 2001, Pubmed
Sergeeva, Fragrant dioxane derivatives identify beta1-subunit-containing GABAA receptors. 2010, Pubmed , Xenbase
Sieghart, Allosteric modulation of GABAA receptors via multiple drug-binding sites. 2015, Pubmed
Sieghart, Affinity of various ligands for benzodiazepine receptors in rat cerebellum and hippocampus. 1984, Pubmed
Sigel, Mapping of the benzodiazepine recognition site on GABA(A) receptors. 2002, Pubmed
Thompson, Salicylidene salicylhydrazide, a selective inhibitor of beta 1-containing GABAA receptors. 2004, Pubmed , Xenbase
Tretter, Stoichiometry and assembly of a recombinant GABAA receptor subtype. 1997, Pubmed
Ueno, Subunit mutations affect ethanol actions on GABA(A) receptors expressed in Xenopus oocytes. 1999, Pubmed , Xenbase
Varagic, Subtype selectivity of α+β- site ligands of GABAA receptors: identification of the first highly specific positive modulators at α6β2/3γ2 receptors. 2013, Pubmed , Xenbase
Varagic, Identification of novel positive allosteric modulators and null modulators at the GABAA receptor α+β- interface. 2013, Pubmed , Xenbase
Yagle, [3H]Ethynylbicycloorthobenzoate ([3H]EBOB) binding in recombinant GABAA receptors. 2003, Pubmed